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coating cell culture bottles and modiﬁed CGM is a more superior
method, which lays the foundation for the further experimental
study.
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Effect of Rosiglitazone on Insulin Resistance and ROS/IKK Signaling
Pathway in Vascular Endothelial Cells
Fanghui Chen
The First Afﬁliated Hospital of Gannan Medical University
OBJECTIVES To explore the protective effect of rosiglitazone on in-
sulin resistance (IR) induced by high glucose in vascular endothelial
cells and its possible mechanism.
METHODS Human umbilical vein endothelial cells (HUVECs) was
divided into 3 groups: the normal control group cultivated in DEME
medium with 5.5 mmol/L glucose; the high glucose group (HG)
cultivated in DEME medium with 33 mmol/L glucose for 24 h after the
IR model was set up; the rosiglitazone group cultivated in DEME
medium with 33 mmol/L glucose and 10 mmol/L of rosiglitazone for
24 h after the IR model was set up. The cell viability, nitric oxide(NO),
endothelin-1(ET-1), mitochondrial membrane potential, reactive oxy-
gen species(ROS), p-IKK and IkBa protein levels were detected.
RESULTS Compared with the normal control, the cell viability, the
level of NO and the mitochondrial membrane potential were
decreased, levels of ET-1 and ROS increased, p-IKK expression was
upregulated, and IkBa expression was down-regulated in HG group(all
P<0.01). Rosiglitazone reversed these changes(P<0.05).
CONCLUSIONS Rosiglitazone has the protective effect on insulin
resistance induced by high glucose in vascular endothelial cells via
inhibiting ROS/IKK signaling pathway.GW26-e2914
A study of the mechanism of valsartan pre-protecting adriamycin-induced
cardiotoxicity
Lili Meng, Qin Yu
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OBJECTIVES To investigate the effects of valsartan pre-protects
adrimycin-induced cardiotoxicity and the mechanism.
METHODS 61 of 8w SD rats were devided into 4groups as follows:
Control group (n¼9) were feeded normally; adrimycin-induced car-
diotoxicity() group:intraperitoneal ADR,2.5mg/(kg.w), totally 6 weeks,
cumulative dose was 15mg/kg. Group C (n¼17): valsartan (low dose)
intervened (VLD) group, Group D: valsartan(high dose) intervened
group(VHD). In group C and D, valsartan was separately (10mg/(kg.d)
and30mg/(kg.d)) given from the ﬁrst dose of adriamycin, totally 6
weeks. After 6 weeks administration of valsartan and adriamycin,
observed 4 weeks. Use echocardiography to detect LVEF, LVFS,
LVESD, LVEDD. Take the heart out of the chest to do measure hearts’
weight. And then do HE, Sirius red staining. Count out CVF. Use ELISA
kits to detect the content of RAS and ROS in cardiac tissues. Use qRT-
PCR to detect collagen I, collagen III, caspase3 and caspase8’s
expressions.
RESULTS
(1) Compared with blank control group, renin, angiotensin II, aldoste-
rone synthase, ROS in the myocardial tissues of the model group are
evidently overexpressed (P <0.05); In group model, rats’ myocardial
tissue, caspase3, caspase8 mRNA levels increased signiﬁcantly
(P <0.05), the myocardial collagen volume increased signiﬁcantly
(P<0.05).
(2) Valsartan high dose group compared with blank control group, there
was no signiﬁcant statistical differences about indexes above (P
>0.05). compared with model control group, the valsartan high dose
group and the blank control group, there were signiﬁcant differences
about the above indexes (P < 0.05).
(3) There were no signiﬁcant differences in LVEDD among the four
groups (P >0.05); About LVESD, LVEF, LVFS, there were no signiﬁ-
cant difference between the valsatan low dose group and the model
control group. The above index average were less than the model
control group and the valsartan low dose group, The differences
among the three groups were signiﬁcant (P <0.05), Compared with
the high dose group and the blank control group, the above indexes
in model control group were higher. The differences were
signiﬁcant(P <0.05). There were no difference between the valsartan
high dose group and blank control group (P >0.05).CONCLUSIONS
(1) Adriamycin might via activing RAS in rats’ myocardial tissues to
cause angiotensin overexpressed. Angiotensin-stimulatied to
generate more ROS. So the superabundant ROS caused the myocar-
dial apoptosis and ﬁbrosis.
(2) Appling enough dose (load dose) valsartan from the ﬁrst dose of
adriamycin could against AT1 in rats’ myocardial tissues. So it could
down-regulate the expression of NOX1 and NOX4 and the ROS
decreased. In the end, the myocardial apoptosis and ﬁbrosis would
be alleviated. However early application of small dose valsartan had
no protective effect on adriamycin induced cardiotoxicity.
(3) Sufﬁcient and early use of valsartan in adriamycin chemotherapy
rats could prevent rats suffering Cardiotoxicity. The mechanism
might related to NOX1 and NOX4 mediated oxidative stress.GW26-e2924
Endothelial progenitor cells join in HHcy impaired angiogenesis
Xiao Huang, Hong Wang, Xiaoshu Cheng
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OBJECTIVES During the last decade,we and others have demonstrated
that HHcy can inhibit endothelial cell growth and postinjury reendo-
thelialization, accelerate neointimal formation, also can impair endo-
thelial relaxation, stimulate vascular smooth muscle cell proliferation,
and inhibit high-density lipoprotein biosynthesis. However, the
fundamental basis of HHcy-impaired angiogenesis remains unknown,
especially the role of endothelial progenitor cells in angiogenesis.
Role of endothelial progenitor cell in HHcy impaired angiogenesis.
Intravenous transfusions of Sca-1þ cells maybe play a role in HHcy MI
mice angiogenesis.
METHODS
1. Angiogenesis of HHcy mice under myocardial infarction. 1.1 Car-
diac function was measured with echocardiography (VisualSonics
Vevo 770); 1.2 Hearts were moved at 2 weeks/6 weeks after myocardial
infarction and kept at -80C until needed. Frozen heart tissues were
cut into 5mm thick slices. Adjacent sections (taken at the midpoint
between LAD ligation site and apex) were stained with rabbit poly-
clonal antibodies against CD31.
2. Flow cytometry analysis. A volume of 200ml peripheral blood/
bone marrow were incubated for 30 minutes in the dark with mono-
clonal antibodies against mouse vascular endothelial growth factor
receptor 2 (VEGFR2) followed by PE-conjugated secondary antibody.
3. MACS Separation-purify Sca-1þ cells. Purity of Sca-1þ cell is based
on the use of MACS MicroBeads, MACS Columns and MACS Separators.
4. Intravenous transfusions of Sca-1þ cells in HHcy MI mice angio-
genesis. To evaluate the homing to infarcted heart of injected cells,
200ml puriﬁed Sca-1þ cells were labeled with CellVueR NIR (near-
infrared) 780 (Excitation max: 745nm/Emission max: 776nm, Mol.
Targeting Tech. Inc. West Chester, PA) and injected peri-orbitally into
C57/B6 mice, 6 hours before MI procedure.
RESULTS
1. HHcy impairs mouse cardiac function. Ejection fraction (EF) and
fractional shortening (FS) were lower in HHcy mice group than control
group, as well as heart capillary density. HHcy mice hearts have
depressed function and less capillary density after myocardial
infarction stress. Survival rate is also lower in HHcy mice.
2. Peripheral blood derived EPC percentage decreased in HHcy mice
group and bone marrow derived EPC percentage is higher in HHcy
mice group, but cell death rate is also higher in HHcy mice.
3. Intravenous transfusion of Sca-1þ cells treatment induce PB derived
EPC percentage increase in both control mice group and HHcy mice
group. 6 weeks survival rate increased from 12.5% to 27.3% in
hCBSþCbs-/- cell treat group, and also 62.5% to 80% in hCBSþCbsþ/- cell
treat group; The LVEF increased from 19.3% to 38.5% in hCBSþCbs-/- cell
treat group, and also 31.6% to50.9% in hCBSþCbsþ/- cell treat group.
CONCLUSIONS EPC joined angiogenesis after myocardial infarction
which is so important to cardiac function. Cell treatment restores
ischemia-induced angiogenesis in HHcy mice.
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Plaque Thrombosis Are Reduced by Attenuating Plaque Inﬂammation with
Pioglitazone and Are Evaluated by Fluorodeoxyglucose Positron Emission
Tomography
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